Kokkali, S.; Saloustros, E.; Stefanou, D.; Makrantonakis, P.; Kentepozidis, N.; Boukovinas, I.; Xenidis, N.; Katsaounis, P.; Ardavanis, A.; Ziras, N.;
et al. Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group. Curr. Oncol. 2022, 29, 1237-1251.
https://doi.org/10.3390/curroncol29020105
AMA Style
Kokkali S, Saloustros E, Stefanou D, Makrantonakis P, Kentepozidis N, Boukovinas I, Xenidis N, Katsaounis P, Ardavanis A, Ziras N,
et al. Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group. Current Oncology. 2022; 29(2):1237-1251.
https://doi.org/10.3390/curroncol29020105
Chicago/Turabian Style
Kokkali, Stefania, Emmanouil Saloustros, Dimitra Stefanou, Paris Makrantonakis, Nikolaos Kentepozidis, Ioannis Boukovinas, Nikolaos Xenidis, Panagiotis Katsaounis, Alexandros Ardavanis, Nikolaos Ziras,
and et al. 2022. "Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group" Current Oncology 29, no. 2: 1237-1251.
https://doi.org/10.3390/curroncol29020105
APA Style
Kokkali, S., Saloustros, E., Stefanou, D., Makrantonakis, P., Kentepozidis, N., Boukovinas, I., Xenidis, N., Katsaounis, P., Ardavanis, A., Ziras, N., Christopoulou, A., Rigas, G., Kalbakis, K., Vardakis, N., Emmanouilides, C., Athanasiadis, I., Anagnostopoulos, A., Hatzidaki, D., Prinarakis, E.,
... Georgoulias, V.
(2022). Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group. Current Oncology, 29(2), 1237-1251.
https://doi.org/10.3390/curroncol29020105
